vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Strawberry Fields REIT, Inc. (STRW). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $40.1M, roughly 1.9× Strawberry Fields REIT, Inc.). On growth, Strawberry Fields REIT, Inc. posted the faster year-over-year revenue change (31.5% vs -36.9%). Over the past eight quarters, Strawberry Fields REIT, Inc.'s revenue compounded faster (20.0% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Strawberry Fields REIT, Inc. is a real estate investment trust focused on healthcare-related real estate assets. It owns, operates and manages skilled nursing facilities, senior living communities, and medical office buildings, primarily serving markets across the United States for healthcare providers and elderly care operators.

MED vs STRW — Head-to-Head

Bigger by revenue
MED
MED
1.9× larger
MED
$75.1M
$40.1M
STRW
Growing faster (revenue YoY)
STRW
STRW
+68.4% gap
STRW
31.5%
-36.9%
MED
Faster 2-yr revenue CAGR
STRW
STRW
Annualised
STRW
20.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
STRW
STRW
Revenue
$75.1M
$40.1M
Net Profit
$2.0M
Gross Margin
69.4%
Operating Margin
-10.4%
52.4%
Net Margin
5.0%
Revenue YoY
-36.9%
31.5%
Net Profit YoY
37.6%
EPS (diluted)
$-1.64
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
STRW
STRW
Q4 25
$75.1M
$40.1M
Q3 25
$89.4M
$39.7M
Q2 25
$105.6M
$37.9M
Q1 25
$115.7M
$37.3M
Q4 24
$119.0M
$30.5M
Q3 24
$140.2M
$29.5M
Q2 24
$168.6M
$29.3M
Q1 24
$174.7M
$27.8M
Net Profit
MED
MED
STRW
STRW
Q4 25
$2.0M
Q3 25
$-2.3M
$2.0M
Q2 25
$2.5M
$2.0M
Q1 25
$-772.0K
$1.6M
Q4 24
$1.5M
Q3 24
$1.1M
$944.0K
Q2 24
$-8.2M
$938.0K
Q1 24
$8.3M
$746.0K
Gross Margin
MED
MED
STRW
STRW
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
STRW
STRW
Q4 25
-10.4%
52.4%
Q3 25
-4.6%
56.6%
Q2 25
-1.0%
54.5%
Q1 25
-1.1%
54.1%
Q4 24
0.6%
51.5%
Q3 24
1.5%
54.4%
Q2 24
-4.7%
52.3%
Q1 24
4.5%
51.3%
Net Margin
MED
MED
STRW
STRW
Q4 25
5.0%
Q3 25
-2.5%
5.1%
Q2 25
2.3%
5.2%
Q1 25
-0.7%
4.2%
Q4 24
4.8%
Q3 24
0.8%
3.2%
Q2 24
-4.8%
3.2%
Q1 24
4.8%
2.7%
EPS (diluted)
MED
MED
STRW
STRW
Q4 25
$-1.64
$0.15
Q3 25
$-0.21
$0.16
Q2 25
$0.22
$0.16
Q1 25
$-0.07
$0.13
Q4 24
$0.08
$0.17
Q3 24
$0.10
$0.14
Q2 24
$-0.75
$0.14
Q1 24
$0.76
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
STRW
STRW
Cash + ST InvestmentsLiquidity on hand
$167.3M
$31.8M
Total DebtLower is stronger
$794.7M
Stockholders' EquityBook value
$198.9M
$12.1M
Total Assets
$248.0M
$885.2M
Debt / EquityLower = less leverage
65.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
STRW
STRW
Q4 25
$167.3M
$31.8M
Q3 25
$173.5M
$19.8M
Q2 25
$162.7M
$96.3M
Q1 25
$164.6M
$42.3M
Q4 24
$162.3M
$48.4M
Q3 24
$170.0M
$29.3M
Q2 24
$163.5M
$16.1M
Q1 24
$156.4M
$15.1M
Total Debt
MED
MED
STRW
STRW
Q4 25
$794.7M
Q3 25
$779.4M
Q2 25
$794.1M
Q1 25
$715.5M
Q4 24
$673.9M
Q3 24
$584.5M
Q2 24
$555.0M
Q1 24
$560.4M
Stockholders' Equity
MED
MED
STRW
STRW
Q4 25
$198.9M
$12.1M
Q3 25
$214.7M
$14.2M
Q2 25
$216.0M
$15.5M
Q1 25
$211.0M
$19.6M
Q4 24
$210.1M
$18.2M
Q3 24
$207.3M
$12.6M
Q2 24
$205.3M
$7.4M
Q1 24
$211.0M
$7.5M
Total Assets
MED
MED
STRW
STRW
Q4 25
$248.0M
$885.2M
Q3 25
$268.2M
$880.6M
Q2 25
$269.3M
$897.3M
Q1 25
$280.0M
$834.8M
Q4 24
$284.2M
$787.6M
Q3 24
$291.2M
$661.5M
Q2 24
$293.5M
$635.9M
Q1 24
$302.8M
$634.9M
Debt / Equity
MED
MED
STRW
STRW
Q4 25
65.64×
Q3 25
54.70×
Q2 25
51.26×
Q1 25
36.47×
Q4 24
37.09×
Q3 24
46.34×
Q2 24
74.61×
Q1 24
74.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
STRW
STRW
Operating Cash FlowLast quarter
$-5.3M
$90.0M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
44.62×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
STRW
STRW
Q4 25
$-5.3M
$90.0M
Q3 25
$12.1M
$20.7M
Q2 25
$-3.4M
$29.8M
Q1 25
$3.4M
$19.0M
Q4 24
$-4.9M
$59.3M
Q3 24
$9.1M
$11.8M
Q2 24
$13.1M
$20.6M
Q1 24
$7.3M
$2.1M
Free Cash Flow
MED
MED
STRW
STRW
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
MED
MED
STRW
STRW
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
MED
MED
STRW
STRW
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
MED
MED
STRW
STRW
Q4 25
44.62×
Q3 25
10.26×
Q2 25
-1.36×
15.24×
Q1 25
11.97×
Q4 24
40.44×
Q3 24
8.04×
12.53×
Q2 24
21.93×
Q1 24
0.88×
2.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons